Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
VS-5584
Potential treatment - theoretical effect Experimental Antiviral Nov/05/2020
Setileuton
Potential treatment - theoretical effect Experimental Antiviral Nov/05/2020
Nb21
Potential treatment - pre-clinical evidence Experimental Antiviral Nov/05/2020
Nb213
Potential treatment - pre-clinical evidence Experimental Antiviral Nov/05/2020
Nb203
Potential treatment - pre-clinical evidence Experimental Antiviral Nov/05/2020
2-(3-(3-Chloro-4-fluorobenzoyl)-7-fluoro-4-hydroxy-1,1-dioxido-2H-benzo[e][1,2]thiazin-2-yl)-N-(4-(trifluoromethyl)phenyl)acetamide
Potential treatment - theoretical effect Experimental Antiviral Nov/04/2020
Sb23
Potential treatment - pre-clinical evidence Experimental Antiviral Nov/04/2020
BNTX
Potential treatment - pre-clinical evidence Experimental Antiviral Nov/04/2020
TMCB
Potential treatment - theoretical effect Experimental Antiviral Nov/03/2020
4E1RCat
Potential treatment - theoretical effect Experimental Antiviral Nov/03/2020
rbIFN-λ
Potential treatment - pre-clinical evidence Experimental Antiviral Nov/03/2020
anti-spike-S1 IgYs
Potential treatment - pre-clinical evidence Experimental Antiviral Nov/03/2020
Lenzilumab
Potential treatment - clinical evidence Experimental Other treatment Nov/01/2020
BC 007
Potential treatment - pre-clinical evidence Experimental Antiviral Oct/31/2020
Thymosin α1
Potential treatment - clinical evidence Experimental Antiviral Oct/31/2020
RBD-16GS-I53-50
Potential treatment - pre-clinical evidence Experimental Vaccine Oct/30/2020
RBD-12GS-I53-50
Potential treatment - pre-clinical evidence Experimental Vaccine Oct/30/2020
MAW-22
Potential treatment - theoretical effect Experimental Antiviral Oct/30/2020
2′-C-methylguanosine
Potential treatment - theoretical effect Experimental Antiviral Oct/29/2020
(2R,3R,4R,5R)-2-(4-Amino-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol
Potential treatment - pre-clinical evidence Experimental Antiviral Oct/29/2020